Rutten-van Molken, Maureen P.M.H.; van Nooten, Floortje E. - In: PharmacoEconomics 25 (2007) 8, pp. 695-711
Rationale: Roflumilast is an oral, once-daily phosphodiesterase IV (PDE4) inhibitor under investigation for chronic … obstructive pulmonary disease (COPD). This study investigated the cost effectiveness of roflumilast in patients with severe to … roflumilast 500mug once daily (n = 761) or placebo (n = 753). Patients in both treatment groups were allowed to receive active …